Search PubMed⌕ Search

Biomedical subjects

L Kish

Publications and source records attributed to L Kish.

13 recordsLinked to original sources
PubMed1998

Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

The Bayer Immuno 1 PSA Assay measures total PSA in human serum and demonstrates excellent performance with an interassay CV < or = 3.4% and a biological detection limit of 0.03 microgram/L. No significant interference from common hormonal and chemotherapeutic drugs, kallikrein, prostatic acid phosphatase, and trypsin, or elevated levels of total bilirubin, hemoglobin, triglycerides, and IgG was observed. The 95th percentile values for healthy individuals increased with age from 3.0 micrograms/L for males 50-59 years and 3.3 micrograms/L for males 60-69 years, to 4.6 micrograms/L for males > or = 70 years. Clinical studies with retrospective samples demonstrated correspondence between serial measurements of PSA and clinical outcome for 98% of 159 prostate cancer patients. Clinical sensitivity for patients with clinical evidence of disease, untreated at the time of specimen draw, increased with increasing stage from 77.5-100%. Specificity of 60-70% for BPH and other benign urogenital diseases was consistent with previous findings. Bayer Immuno 1 PSA Assay values for 2131 specimens from healthy subjects and patients with prostate cancer, BPH, and other malignant and nonmalignant diseases correlated well with the Abbott IMx PSA Assay over the range 0.0-6,238 micrograms/L (Y = 1.10 x + 0.02). The Bayer Immuno 1 PSA Assay provides automated ultrasensitive, precise, and equimolar measurement of total PSA in human serum.

Aged↗
PubMed1998

Multicenter evaluation of the Bayer Immuno I CA 15-3 assay.

We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1 CA 15-3 assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV < or = 4%. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1%). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT BR 27.29 and Centocor CA 15-3 RIAs (r > or = 0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11% and 21% for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.

Adolescent↗
PubMed1996

The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2.

CD2, a cell surface glycoprotein expressed on T cells and natural killer cells, can couple to signaling pathways that result in T cell proliferation. An Src-like protein tyrosine kinase, p56lck, coprecipitates with CD2, and perturbation of CD2 by monoclonal antibodies results in an increase in the activity of p56lck, suggesting that an interaction with p56lck contributes to CD2-mediated signaling. Herein, we investigate the mechanism by which CD2 associates with p56lck. We demonstrate that CD2 and p56lck associate when coexpressed in nonlymphoid cells, that this association requires the cytoplasmic domain of CD2, and that the SH3 domain of p56lck mediates its interactions with CD2. Using truncation mutants of CD2, we identify two regions in the cytoplasmic domain of CD2 involved in binding p56lck. Each region contains a proline-rich sequence that, in the form of a synthetic peptide, directly binds p56lck. Thus, proline-rich sequences in the cytoplasmic domain of CD2 allow this transmembrane receptor to bind to the SH3 domain of p56lck.

Amino Acid Sequence↗
PubMed1994

Statistical medicine.

In the Perspective by Donald G. York (8 July, p. 191), figure 1 was printed incorrectly. The correct figure and caption appear below. [See figure in the PDF file]

Education, Medical↗
PubMed1994

Multipopulation survey designs: five types with seven shared aspects.

"Five types of multipopulation surveys are defined and described: periodic surveys; multidomain designs; multinational survey designs; cumulated and combined samples; and controlled observations or quasi- experimental designs. I emphasize the deliberate designs of these surveys, not the mere post hoc or ad hoc utilization of survey results. Most importantly, I emphasize a sharp distinction between seven listed aspects. Similarity and standardization of the survey aspects (definitions, methods, measurements) are essential to avoid biases in comparisons, though admittedly difficult. In contrast, flexibility in sampling designs and sizes, to reduce variances, is permissible, also desirable to reduce variances and costs." (SUMMARY IN FRE)

Data Collection↗
PubMed1994

The effect of cycloplegia on measurement of the ocular components.

PURPOSE: The purpose of this study was to examine the effect of cycloplegic agent on the measurement of refractive error and the ocular components. METHODS: We compared two commonly used topical cycloplegic agents, 1% tropicamide and 1% cyclopentolate, for their effect on the measurement of refractive error (by Canon R-1 autorefraction), accommodative response (by Canon R-1 autorefraction and by the conventional, subjective "pushup" method), crystalline lens power (by video phakometry and by calculation), and axial ocular dimensions (by A-scan ultrasonography) in 20 emmetropic to moderately hyperopic children. RESULTS: Comparison of refractive error at each drug's reported time of maximum cycloplegia (30 minutes for tropicamide and 60 minutes for cyclopentolate) showed that distance autorefraction in the vertical meridian differed by +0.20 +/- 0.30 diopters (D) (P = 0.008). The average difference was +0.07 +/- 0.10 mm for anterior chamber depth (P = 0.004), -0.03 +/- 0.05 mm for crystalline lens thickness (P = 0.025), -0.65 +/- 0.69 D for phakometrically measured crystalline lens power (P < 0.001), +0.03 +/- 1.55 D for calculated crystalline lens power (P = 0.94), and -0.09 +/- 0.19 mm for vitreous chamber depth (P = 0.062, all paired t tests; positive signs denote greater values with cyclopentolate). Residual accommodation was 0.47 and 0.67 D greater with tropicamide when measured by autorefraction and the pushup method (P = 0.013 and 0.08 respectively, paired t test). All significant differences were consistently in the direction of poorer cycloplegia with tropicamide. CONCLUSIONS: Although tropicamide, as expected, showed poorer cycloplegia compared to cyclopentolate, the degree of difference appeared to be small, with minimal effect on the measurement of distance refractive error and the ocular optical components.

Accommodation, Ocular↗
PubMed1993

[Modification of RNA ligase histidine residues by diethylpyrocarbonate].

The practicality of Tris-HCl buffer for modification of histidine residues by diethylpyrocarbonate (DEPC) was studied using a model protein-hexokinase. It was found that modification was selective at pH 7.5. Conditions for modification of one histidine residue in the protein molecule were specified. In 30 mM Tris-HCl buffer pH 7.5, 10-min interaction of RNA-ligase with 0.3 mM DEPC was accompanied by modification of one histidine residue, as a result of which the ability to form a covalent AMP-RNA-ligase complex decreased 3 times. Modification of two histidine residues of RNA-ligase resulted in a complete loss of the enzyme activity. At increasing DEPC concentration modification affected all of the seven histidine residues of RNA-ligase. The kinetic parameters (Km and V) for the native and modified enzymes were determined and compared.

Diethyl Pyrocarbonate↗
PubMed1986

Complete censuses and samples.

"Complete decennial censuses are needed for small areas and other domains. Sample surveys yield diverse and timely data. Censuses can also be combined with samples, and sometimes with data from registers, for diverse estimates that are detailed over both space and time, and hence are timely for small domains. Methods of 'postcensal estimates' for small domains are described. We note uses of censuses for improving samples and of samples for improving censuses, and propose a method for cumulating data from 'rolling' (or rotating) periodic (weekly, monthly or quarterly) samples specifically designed to cover the population in detail over designed spans (annual and quinquennial)."

Censuses↗
PubMedDate not supplied

Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay.

We conducted a multicenter evaluation of the analytical and clinical performance of the automated Bayer Immuno 1 complexed PSA (cPSA) assay, and compared assay performance to the Bayer Immuno 1 PSA assay. We sought to determine whether measurements of cPSA could be of clinical utility in the management of patients with prostate cancer. Results of the 10-day imprecision across three evaluation sites produced total CV < 2.50% and an analytical sensitivity of 0.02 microgram/L. There was an increased trend in clinical sensitivity for prostate cancer with increasing stage of disease (71-86%). Clinical specificity for patients with benign urogenital disease was 74.8%, and for other nonprostate diseases ranged from 91.1-100%. Retrospective serial monitoring of 155 patients with prostate cancer demonstrated concordance of cPSA measurements to clinical status for 97% of the patients analyzed. Results from the clinical studies using the Bayer Immuno 1 cPSA assay were comparable to results obtained with the Bayer Immuno 1 PSA assay. The Bayer Immuno 1 cPSA assay demonstrates analytical performance and clinical effectiveness in the management of prostate cancer patients during the course of disease and therapy.

Adolescent↗